Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 May 16;5(2):23.
doi: 10.3390/biomedicines5020023.

Advances in the Use of Regulatory T-Cells for the Prevention and Therapy of Graft-vs.-Host Disease

Reshma Ramlal  1 , Gerhard C Hildebrandt  2
Affiliations
Review

Advances in the Use of Regulatory T-Cells for the Prevention and Therapy of Graft-vs.-Host Disease

Reshma Ramlal et al. Biomedicines. .

Abstract

Regulatory T (Tregs) cells play a crucial role in immunoregulation and promotion of immunological tolerance. Adoptive transfer of these cells has therefore been of interest in the field of bone marrow and solid organ transplantation, autoimmune diseases and allergy medicine. In bone marrow transplantation, Tregs play a pivotal role in the prevention of graft-verus-host disease (GvHD). This has generated interest in using adoptive Treg cellular therapy in the prevention and treatment of GvHD. There have been several barriers to the feasibility of Treg cellular therapy in the setting of hematopoietic stem cell transplantation (HSCT) which include low Treg concentration in peripheral blood, requiring expansion of the Treg population; instability of the expanded product with loss of FoxP3 expression; and issues related to the purity of the expanded product. Despite these challenges, investigators have been able to successfully expand these cells both in vivo and in vitro and have demonstrated that they can be safely infused in humans for the prevention and treatment of GvHD with no increase in relapse risk or infections risk.

Keywords: CD4+CD25+FoxP3+ T cells; Tregs; adoptive cellular therapy; graft versus host disease (GvHD).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Ruutu T., Gratwohl A., de Witte T., Afanasyev B., Apperley J., Bacigalupo A., Dazzi F., Dreger P., Dreger P., Duarte R., et al. Prophylaxis and treatment of GvHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant. 2014;49:168–173. doi: 10.1038/bmt.2013.107. - DOI - PubMed
    1. Choi S.W., Reddy P. Current and emerging strategies for the prevention of graft-versus-host disease. Nat. Rev. Clin. Oncol. 2014;11:536–547. doi: 10.1038/nrclinonc.2014.102. - DOI - PMC - PubMed
    1. Baecher-Allan C., Brown J.A., Freeman G.J., Hafler D.A. CD4+CD25high regulatory cells in human peripheral blood. J. Immunol. 2001;167:1245–1253. doi: 10.4049/jimmunol.167.3.1245. - DOI - PubMed
    1. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune response. Annu. Rev. Immunol. 2004;22:531–562. doi: 10.1146/annurev.immunol.21.120601.141122. - DOI - PubMed
    1. Beres A.J., Drobyski W.R. The role of regulatory T cells in the biology of graft versus host disease. Front. Immunol. 2013;4:163. doi: 10.3389/fimmu.2013.00163. - DOI - PMC - PubMed